Pragmatic Research of Acupuncture and Counseling eXtended to Inpatient Services (PRACXIS)
21 de outubro de 2021 atualizado por: University of California, San Francisco
Non-pharmacologic Approaches to Relieve Pain and Symptom Distress Among Diverse Hospitalized Cancer Patients
Despite improved assessment and pharmacologic management, cancer pain is still undertreated.
Using non-pharmacologic treatments alongside medications may better address patients' total pain experience by relieving physical and psychological symptoms and reducing the adverse effects of drugs.
However, our knowledge of the benefits of multidisciplinary approaches in real-world hospital settings is limited.
Patients want to know "How can I get the most pain relief with the fewest side effects?"
This study proposal is designed to address this question by testing how combining pharmacologic and non-pharmacologic (acupuncture and pain counseling) treatments can: (1) maximize effectiveness, (2) minimize harms, and (3) align with patients' preferences.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Descrição detalhada
This study compares clinically-relevant therapeutic options in two high-volume hospitals (one public, one university) to address the core research question of whether non-pharmacologic approaches improve symptom management among diverse inpatients. Study investigators will assess the effectiveness of acupuncture and of pain counseling independently and in combination.
Participants will be randomized to two factors each with two levels, yielding four experimental conditions: (1) standard pharmacologic pain management, (2) pharmacologic pain management + acupuncture, (3) pharmacologic pain management + pain counseling, (4) pharmacologic pain management + acupuncture + pain counseling. Patient outcomes will be assessed using a mixed-methods approach, with validated scales for quantitative measures and qualitative interviews to elicit stakeholder perspectives (patients, caregivers, providers).
The study will be conducted as a pragmatic clinical trial at two hospitals to address these aims:
- Determine the effectiveness of adjunctive acupuncture and of pain counseling for improving pain management.
- Determine the extent that adjunctive acupuncture and pain counseling reduce use of opioid analgesics and side effects.
- Examine stakeholder perspectives on non-pharmacologic approaches to pain management.
Tipo de estudo
Intervencional
Inscrição (Real)
448
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
California
-
San Francisco, California, Estados Unidos, 94143
- University of California, San Francisco
-
San Francisco, California, Estados Unidos, 94110
- Zuckerberg San Francisco General Hospital
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
21 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Patients admitted to University of California San Francisco (UCSF) or Zuckerberg San Francisco General (ZSFG) with a malignant solid tumor
- Speak Cantonese, English, or Spanish
- Have an anticipated stay of ≥ 48 hours
- Be aged 21 or older
- Have pain intensity of ≥ 4 out of 10 for worst pain in the prior 24 hours when enrolled
Exclusion Criteria:
- Acupuncture contraindication
- Unstable medical condition (e.g., severe pulmonary disease, myocardial infarction)
- Admission to the psychiatric ward (e.g., for severe depression)
- Inability to consent (e.g., cognitive impairment)
- Prior involvement with the study (e.g., readmissions)
- Platelets < 50,000 microliters
- Absolute neutrophil count < 500 microliters
- C. difficile infection
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição fatorial
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Sem intervenção: Treatment As Usual
Participants will receive routine care consisting of usual analgesic medications for pain in adults with cancer.
|
|
|
Comparador Ativo: Acupuncture
Along with routine pain medications, participants will be offered daily acupuncture treatments for up to four days.
|
A licensed acupuncturist will assess participants' symptoms and administer acupuncture needles in accordance with traditional Chinese medicine principles and the study protocol.
Treatments will provided daily for up to four hospital days.
|
|
Comparador Ativo: Pain Counseling
Along with routine pain medications, participants will receive evidence-based psychosocial support through education and counseling provided by qualified study staff.
|
Participants will receive sessions with a counselor trained in pain management.
The pain counselor will explain, review, and discuss the contents of a Pain Control booklet.
Sessions will include pain assessment, pain education, and coping skills, provided daily for up to four hospital days.
|
|
Comparador Ativo: Acupuncture and Pain Counseling
Along with routine pain medications, participants will be offered daily acupuncture treatments and pain counseling for up to four days as described above.
|
A licensed acupuncturist will assess participants' symptoms and administer acupuncture needles in accordance with traditional Chinese medicine principles and the study protocol.
Treatments will provided daily for up to four hospital days.
Participants will receive sessions with a counselor trained in pain management.
The pain counselor will explain, review, and discuss the contents of a Pain Control booklet.
Sessions will include pain assessment, pain education, and coping skills, provided daily for up to four hospital days.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in worst pain intensity assessed by the NRS
Prazo: Daily for up to four hospital days
|
Participants' worst level of pain in the past 24 hours on a 0-10 numeric rating scale (NRS), 0= no pain and 10= worst pain imaginable
|
Daily for up to four hospital days
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Use of opioids during hospital stay
Prazo: Hospital stay (average length of stay = 5 days)
|
Total and average daily use of opioids based on morphine milligram equivalence
|
Hospital stay (average length of stay = 5 days)
|
|
Presence and severity of common side effects
Prazo: Daily for up to four hospital days
|
Nausea, vomiting, agitation, and sedation
|
Daily for up to four hospital days
|
|
Cancer-related distress
Prazo: Daily for up to four hospital days
|
Single item measure developed by the National Comprehensive Cancer Network.
Participants are asked to indicate the number that best describes how much distress they are experiencing in the past week including today, 0=no distress and 10=extreme distress.
|
Daily for up to four hospital days
|
|
Health-related quality of life assessed by the EuroQol EQ-5D-3L (EQ-5D-3L)
Prazo: Daily for up to four hospital days
|
The EuroQol EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, usual activities, pain/discomfort and anxiety/depression.
Each dimension has 3 levels: no problems, some problems, extreme problems.
The respondent is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions.
The EuroQol visual analogue scale (EQ VAS) records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'.
Detailed scoring instructions are available: https://euroqol.org/wp-content/uploads/2016/09/EQ-5D-3L_UserGuide_2015.pdf
|
Daily for up to four hospital days
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pain Treatment Satisfaction Scale
Prazo: Assessed once at the end of hospital stay (average length of stay = 5 days)
|
The Pain Treatment Satisfaction Scale includes subscales of satisfaction with information, medical care, effectiveness, and side effects with reliability ranging from 0.83 to 0.92.
Each of the subscales are scored from 0 to 100 with higher scores indicating greater satisfaction.
|
Assessed once at the end of hospital stay (average length of stay = 5 days)
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Maria T Chao, DrPH, MPA, University of California, San Francisco
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
17 de janeiro de 2019
Conclusão Primária (Real)
30 de setembro de 2021
Conclusão do estudo (Real)
30 de setembro de 2021
Datas de inscrição no estudo
Enviado pela primeira vez
30 de agosto de 2018
Enviado pela primeira vez que atendeu aos critérios de CQ
3 de abril de 2019
Primeira postagem (Real)
5 de abril de 2019
Atualizações de registro de estudo
Última Atualização Postada (Real)
22 de outubro de 2021
Última atualização enviada que atendeu aos critérios de controle de qualidade
21 de outubro de 2021
Última verificação
1 de outubro de 2021
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- 17-23446
- NCI-2018-02204 (Identificador de registro: NCI Clinical Trials Reporting Program (CTRP))
- 18801 (University of California, San Francisco)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Não
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .